^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    12/04/2020
    Excerpt:
    The NCCN panel recommends (category 1) bevacizumab, cisplatin, and pemetrexed followed by maintenance bevacizumab for bevacizumab-eligible patients with unresectable MPM...The NCCN panel recommends (Category 2A) adding bevacizumab to carboplatin/pemetrexed with or without maintenance bevacizumab as a first-line therapy option for patients with unresectable MPM...
    Secondary therapy:
    carboplatin + pemetrexed; cisplatin + pemetrexed
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Recommendations...First-line systemic therapy...Combination of bevacizumab with platinum–pemetrexed is recommended as first-line systemic therapy option [I, A].
    Secondary therapy:
    pemetrexed
    DOI:
    https://doi.org/10.1016/j.annonc.2021.11.005